Provision of medicines supply chain information: supporting ICU medicines supply during COVID-19 response. Phase Two
This sits in the upper-middle of the Research & Development band — a substantial contract for the sector. Based on 20,405 valued Research & Development tenders in our corpus.
NHS England & Improvement (NHSE&I) require visibility of the medicines supply chain and national stockholding of priority ICU medicines.
Such information supports NHSE&I to allocate and distribute medicines equitably, based on need, to NHS Trusts in England and across the devolved administrations.
An understanding of national stock holdings allows us to plan for shortages, manage shortages and engage with industry on areas for priority manufacture.
Several medicines are in extremely high demand and the profile of use has changed: COVID-19 treatment requires far higher volumes of certain medicines per patient compared to BAU treatment - primarily due to the length of sedation needed.
What the supplier must deliver
NHS England & Improvement (NHSE&I) require visibility
NHS England & Improvement (NHSE&I) require visibility of the medicines supply chain and national stockholding of priority ICU medicines.
Derived from the notice text — always confirm against the original documents.
Make the case to bid
Reveal who to approach at NHS Improvements, and generate a go-to-market strategy from their news, accounts and people.
- OCID
- e3758938-5f82-4fa4-959c-ebcd135271a1
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- 4415/Tender/
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Research & Development
Assembling the market network…
NHS Improvements’s tender network
Assembling the network…